Nabi Biopharmaceuticals-Financial Company Report
Financial Company Reports contain the company's contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues. The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, day's sales outstanding, day's outstanding inventory, cash and short-term investments per share and total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Much of the information contained in the report is included in both tabular and graphic formats.Financial Reports deliver key sophisticated analytical ratios and performance analyses for public biomedical companies. Each report provides an in depth virtual snapshot of a company, enabling the user to better understand its financial position.Scope of the report: Each Life Science Analytics' Financial Report provides extensive information on a company's financial health including: Company contact information and business overviewStock performance historyDividend historyPrice and volume figures, including key price ratios relative to earnings, book value ratios and comparisons, sales, cash flow, and share priceHistorical market-related data including relative strength, valuation, common and diluted shares are presented in graphical form. Each report provides extensive data on return ratios, financial strength, and growth ratios. Convenient historical tables on quarterly and annual income statements, balance sheets and cash flow statements are also included. Key benefits:Data in each Financial Report is presented in both tabular and graphical format providing the user with an efficient assessment of a company's historical performance.Stay ahead of the competition by accessing the latest financial intelligence.Sophisticated financial analysis ratios provide a quick insight into management's effectiveness and the company's ability to meet its short-term obligations.
Published on: Mar 3, 2016
Transcripts - Nabi Biopharmaceuticals-Financial Company Report